Results 31 to 40 of about 22,314 (175)

Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations

Pharmaceuticals, 2021
Stability studies performed by the pharmaceutical industry are principally designed to fulfill licensing requirements. Thus, post-dilution or post-reconstitution stability data are frequently limited to 24 h only for bacteriological reasons, regardless ...
Antonella Iudicello, Filippo Genovese, Valentina Strusi, Massimo Dominici, Barbara Ruozi   +4 more
doaj   +1 more source

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

BMC Cancer, 2017
Background Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading ...
John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, Steve Songer, C. L. Beach, Hervé Dombret   +20 more
doaj   +1 more source

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Haematologica, 2018
Therapy of acute myeloid leukemia in older persons is associated with poor outcomes because of intolerance to intensive therapy, resistant disease and co-morbidities.
Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, CL Beach, Ravi Vij, Xiwei Wang, Jim Zhong, Robert Peter Gale   +12 more
doaj   +1 more source

Development of a Supercritical Fluid Chromatography-Tandem Mass Spectrometry Method for the Determination of Azacitidine in Rat Plasma and Its Application to a Bioavailability Study

Molecules, 2013
Azacitidine is widely used for the treatment of myelodysplastic syndromes (MDS) and acute myelogenous leukaemia (AML). The analysis of azacitidine in biological samples is subject to interference by endogenous compounds.
Dongpo Li, Tianhong Zhang, Longfa Kou, Youxi Zhang, Jin Sun, Zhonggui He   +5 more
doaj   +1 more source

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial

eJHaem, 2023
Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux   +10 more
doaj   +1 more source

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]

, 2016
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus, Diesch, Jeannine, Garz, Anne-Kathrin, Götze, Katharina S., Palau, Anna, Zwick, Anabel   +5 more
core   +2 more sources

Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation

Haematologica, 2016
Advanced myelodysplastic syndrome harbors a high risk of progression to acute myeloid leukemia and poor prognosis. In children, there is no established treatment to prevent or delay progression to leukemia prior to hematopoietic stem cell transplantation.
Nicolas Waespe, Machiel Van Den Akker, Robert J. Klaassen, Lani Lieberman, Meredith S. Irwin, Salah S. Ali, Mohamed Abdelhaleem, Bozana Zlateska, Mira Liebman, Michaela Cada, Tal Schechter, Yigal Dror   +11 more
doaj   +1 more source

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply [PDF]

, 2016
There is an increasing interest on the effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) outside clinical trials. We recently reported the lack of effect of this drug in an unselected population of 821 patients.
Bernal del Castillo, Teresa, Martínez Camblor, Pablo, Sanz, Guillermo, Sánchez García, Joaquín   +3 more
core   +1 more source

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Platelets, 2021
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Francesco D’Alò, Ilaria Zangrilli, Elisa Cupelli, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Emiliano Fabiani, Livio Pagano, Stefan Hohaus, Valerio De Stefano   +9 more
doaj   +1 more source

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts [PDF]

, 2017
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
AM Zeidan, AO Soriano, BD Cheson, BD Cheson, CJ Clopper, D Merkel, DJ DeAngelo, E Raffoux, G Garcia-Manero, G Garcia-Manero, G Garcia-Manero, H Dombret, H Khan, J Babb, JP Issa, JP Issa, JP Laubach, L Maurillo, L Pleyer, M Kirschbaum, M Lubbert, Mikkael A. Sekeres, P Atadja, P Fenaux, P Fenaux, P Maslak, P Tan, PG Richardson, SD Gore, SD Nimer, T Prebet, TE Fandy, W Blum, W Fiskus, Y Ofran, YG Lee   +35 more
core   +2 more sources